H5N1 News and Research

Latest H5N1 News and Research

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

NanoViricides, Inc. reports that its optimized FluCide™ drug candidates achieved dramatic reduction in viral load within the lungs of animals infected with a lethal dose of H1N1 influenza virus.

15 Nov 2010

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010

NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona. The presentation was entitled DAS181 (Fludase), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling.

12 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.

1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

H5N1 lethality gene Replikin Count continues to rise in 2010

BioRadar™ software correctly predicted the 2009 H1N1 (Swine Flu) outbreak a year in advance. The same rise in Replikin Count of these genomic Replikin genes, this time in the H5N1 (Bird Flu) virus, may similarly warn of the coming of severe outbreaks in H5N1.

28 Oct 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

25 Oct 2010

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy.

25 Oct 2010

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.

25 Oct 2010

Union Springs, BIOSAFE enter agreement to commercialize HM4100 products

Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.

22 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

Oseltamivir reduces mortality in influenza A/H5N1 patients

A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or 'bird flu', even when given late in the course of illness.

15 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Scientists identify environmental conditions that could enable H5N1 bird flu virus to survive

On the eve of the 2010-11 influenza flu season, scientists and engineers have identified the environmental conditions and surfaces that could enable a highly pathogenic (H5N1) bird flu virus to survive for prolonged periods of time at least two weeks and up to two months. Among them: The virus appears to thrive at cooler temperatures and low humidity.

14 Oct 2010

Medicago and PATH partner on development of broad coverage influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.

13 Oct 2010

Experts highlight health issues in growing megacities

Experts at the World Health Summit highlighted health concerns related to the growth of megacities, "roughly defined as cities with a population of more than 10 million," Agence France-Presse reports.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

H5N1 News and Research

Latest H5N1 News and Research

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

Sinovac third quarter sales decrease 7% to $9.6 million

NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

H5N1 lethality gene Replikin Count continues to rise in 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Union Springs, BIOSAFE enter agreement to commercialize HM4100 products

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

NanoViricides' President delivers speech at ASNM Second Annual Conference

Oseltamivir reduces mortality in influenza A/H5N1 patients

NanoViricides files financial year end annual report with SEC

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Scientists identify environmental conditions that could enable H5N1 bird flu virus to survive

Medicago and PATH partner on development of broad coverage influenza vaccine

Experts highlight health issues in growing megacities

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in